GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EZZ Life Science Holdings Ltd (ASX:EZZ) » Definitions » Net Current Asset Value

EZZ Life Science Holdings (ASX:EZZ) Net Current Asset Value : A$0.34 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is EZZ Life Science Holdings Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

EZZ Life Science Holdings's net current asset value per share for the quarter that ended in Dec. 2023 was A$0.34.

The historical rank and industry rank for EZZ Life Science Holdings's Net Current Asset Value or its related term are showing as below:

ASX:EZZ' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.19   Med: 1.72   Max: 2.93
Current: 2.88

During the past 4 years, the highest Price-to-Net-Current-Asset-Value Ratio of EZZ Life Science Holdings was 2.93. The lowest was 1.19. And the median was 1.72.

ASX:EZZ's Price-to-Net-Current-Asset-Value is ranked better than
62.55% of 1028 companies
in the Biotechnology industry
Industry Median: 3.94 vs ASX:EZZ: 2.88

EZZ Life Science Holdings Net Current Asset Value Historical Data

The historical data trend for EZZ Life Science Holdings's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EZZ Life Science Holdings Net Current Asset Value Chart

EZZ Life Science Holdings Annual Data
Trend Jun20 Jun21 Jun22 Jun23
Net Current Asset Value
0.18 0.23 0.26 0.33

EZZ Life Science Holdings Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Current Asset Value Get a 7-Day Free Trial 0.23 0.26 0.29 0.33 0.34

Competitive Comparison of EZZ Life Science Holdings's Net Current Asset Value

For the Biotechnology subindustry, EZZ Life Science Holdings's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EZZ Life Science Holdings's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where EZZ Life Science Holdings's Price-to-Net-Current-Asset-Value falls into.



EZZ Life Science Holdings Net Current Asset Value Calculation

EZZ Life Science Holdings's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Jun. 2023 is calculated as

Net Current Asset Value Per Share(A: Jun. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(17.006-3.058-0-0)/42.705
=0.33

EZZ Life Science Holdings's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(19.591-4.999-0-0)/42.705
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EZZ Life Science Holdings  (ASX:EZZ) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


EZZ Life Science Holdings Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of EZZ Life Science Holdings's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


EZZ Life Science Holdings (ASX:EZZ) Business Description

Traded in Other Exchanges
N/A
Address
104 Derby Street, Silverwater, NSW, AUS, 2128
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.

EZZ Life Science Holdings (ASX:EZZ) Headlines

No Headlines